AbbVie, Genmab say Epkinly didn’t prolong overall survival in lymphoma studynews2026-01-16T21:01:22+00:00January 16th, 2026|Endpoints News|
Drugmakers without MFN pacts are bracing to make onenews2026-01-16T20:48:34+00:00January 16th, 2026|Endpoints News|
Supreme Court will hear Hikma’s ‘skinny label’ fight against Amarinnews2026-01-16T20:06:44+00:00January 16th, 2026|Endpoints News|
#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026news2026-01-16T14:42:01+00:00January 16th, 2026|Endpoints News|
European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDAnews2026-01-16T12:10:14+00:00January 16th, 2026|Endpoints News|
Trump asks Congress to codify ‘most favored nation’ dealsnews2026-01-15T19:10:11+00:00January 15th, 2026|Endpoints News|
A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuitnews2026-01-15T17:42:44+00:00January 15th, 2026|Endpoints News|
J&J reports positive Phase 3 data for Tecvayli in earlier blood cancer settingnews2026-01-15T11:52:54+00:00January 15th, 2026|Endpoints News|
Manufacturers benefit as pharma customers invest back in USnews2026-01-14T20:19:22+00:00January 14th, 2026|Endpoints News|
Jazz sells priority review voucher for $200M, scoring highest price in a decadenews2026-01-14T18:44:04+00:00January 14th, 2026|Endpoints News|
